Cavernous Sinus Syndrome as the Presentation of Systemic Non-Hodgkin’s Lymphoma

Khadija Sonda Moalla*, Nouha Farhat, Salma Sakka, Olfa Hdiij, Hanen Haj Kacem, Mariem Damak and Chokri Mhiri
Department of Neurology, Habib Bourguiba University Hospital, Sfax, Tunisia

Abstract

Background: Cavernous sinus (CS) involvement has rarely been reported in malignant lymphoma. CS syndrome is uncommon as an initial presentation of non-Hodgkin’s extra nodal lymphomas.

Case report: A 57-year-old man presented with a one-month history of headache, ocular pain and diplopia. Neurological examination revealed incomplete palsy of the left III and right VI nerves, and sensory loss of the first division of the left trigeminal nerve. Initial Magnetic Resonance Imaging (MRI) suggested left CS thrombosis. Despite optimal anticoagulation therapy, he developed right oculomotor nerve palsy, with ptosis and mydriasis of the left eye and bilateral sensory loss of the first and second division of the trigeminal nerves. MRI demonstrated a homogeneous tissue lesion occupying the CS with moderate gadolinium enhancement. A body scan showed hepatosplenomegaly with hepatic and splenic nodules. The patient underwent percutaneous transhepatic biopsy and the lesion was histologically diagnosed as non-Hodgkin’s lymphoma, diffuse large B-cell type. Tumor cells were positive for CD20, CD79a and KI67. Following four cycles of intravenous and intrathecal chemotherapy, the right oculomotor nerve palsy was completely resolved. There was partial improvement of enhancing lesion noted on follow-up MRI.

Conclusion: CS syndrome is a rare presentation of malignant non-Hodgkin lymphoma. The diagnosis rests largely on imaging and biopsy results. It is associated with poor prognosis and Aggressive combined modality treatment appears to improve survival.

Keywords: Non-Hodgkin lymphoma; Cavernous sinus; MRI; Diplopia

Introduction

Central nervous system involvement by non-Hodgkin lymphoma (NHL) can occur as a late manifestation of systemic NHL and may include mainly mass lesions and meningeal infiltration [1]. Naso-sinus localization of NHL is exceptional and represents only 0.17% [2]. Bilateral cavernous sinus (CS) syndrome is rarely the initial manifestation in immunocompetent adults with systemic NHL. We report here a new case of isolated and inaugural CS manifestation of systemic NHL.

Case Report

A 57-year-old man presented with a one-month history of headache, ocular pain associated with nausea and diplopia. There was no history of fever, weight loss, or nocturnal sweating. Ophthalmological examination revealed incomplete palsy of the left III and right VI nerves, and sensory loss of the first division of the left trigeminal nerve. Fundoscopy was normal. Complete blood count, urinalysis and other routine laboratory tests including blood biochemistry hormonal tests were within normal limits. Viral serologic testing including human immunodeficiency virus (HIV), varicella-zoster virus (VZV) and syphilis serology were negative. Initial Magnetic Resonance Imaging (MRI) showed bulging CS appearing isointense on T1 (a) and T2 FLAIR (b) weighted images with homogenous enhancement and irregular filling defects after gadolinium (c) suggesting an acute thrombus. Second brain MRI (two months after onset) (d/e/f): axial sequences: Expansion of the CS lesion Third brain MRI (six months after onset) (g/h/i): axial sequences: Slight improvement of the enhancing lesion (i).

*Corresponding author: Dr. Khadija Sonda Moalla, Department of Neurology, Habib Bourguiba Hospital - CP 3029, Sfax, Tunisia, Tel: +21622778671; E-mail: m.khdija@hotmail.fr

Received October 08, 2017; Accepted December 12, 2017; Published December 20, 2017

Citation: Moalla KS, Farhat N, Sakka S, Hdiij O, Kacem HH, et al. (2017) Cavernous Sinus Syndrome as the Presentation of Systemic Non-Hodgkin’s Lymphoma. J Clin Case Rep 7: 1061. doi: 10.4172/2165-7920.10001061

Copyright: © 2017 Moalla KS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
normal. A second MRI (two months from onset) demonstrated an expansion of the CS lesion. The masse appeared isointense to the cortex on T1- and T2-weighted images and FLAIR sequence, and enhanced homogeneously after gadolinium. The CS infiltration did not extend into the contiguous regions (Figures 1d-i). No improvement was seen after adjunction of corticotherapy.

With all these features and progressive involvement, to rule out nasopharyngeal growth which was suspected on MRI, the patient was planned for nasal endoscopy. On the endoscopy, growth was observed in right side of nasopharynx near to fossa of Rosenmuller but the biopsy was negative. A second laboratory studies showed elevated liver enzymes (AST: 413 IU/L; ALT: 459 IU/L), C-reactive protein level was increased (79.3 mg/l) and there was a marked elevation in the level of lactate dehydrogenase (LDH) (646 IU/L) suggesting the presence of tumor lysis syndrome. A body scan was perfomed showing hepatosplenomegaly with hepatic and splenic nodules (Figures 2a and 2b). The patient underwent percutaneous transhepatic biopsy and the lesion was histologically diagnosed as NHL, diffuse large B-cell type. Tumor cells were positive for CD20, CD79a and Ki67 (Figures 3a and 3b). Tumor tissue; white arrow: normal tissue

References

| Age/ Gender | Inaugural symptoms | Clinical signs | Histology | Treatment | Outcome |
|-------------|--------------------|----------------|-----------|-----------|---------|
| 44/M        | Left Ptosis and complete ophthalmoplegia | Incomplete left pupil constriction, sensory disturbance in the left V1 with diminished corneal sensation | Undifferentiated ML | Death within 23 days from the onset |
| 61/M        | Vertical diplopia, right ptosis and blurred vision | Right partial III palsy with pupillary dilatation, complete VI palsy and sensory impairment in the right V1 | ML | RT | Relief of pain, visual acuity remained at finger counting and complete ophthalmoplegia |
| 43/NA       | NA | NA | Diffuse histiocytic | NA | NA |
| 46/M        | Diplopia, parasthesia and pain in the right orbit | Paralysis of the right VI nerve and reduced visual acuity at 5/10 | Lymphosarcoma | CT/ RT | *Death 7 months after the onset from marrow aplasia |
| 70/F        | Diplopia, right ptosis and pain in the right orbit | Paralysis in the right III and loss of sensation in the area supplied by the right V | Lymphosarcoma | RT | Death 13 months after the onset |
| 45/NA       | NA | NA | ML | NA | NA |
| 40/M        | Diplopia with right orbital pain | Complete right VI palsy | Large cell immunoblastic | RT | Died 3 and ½ months after the onset |
| 4/F         | Sudden squinting in both eyes and headache | Bilateral abducens and right trochlear palsy | Small, noncleaved NHL | CT | *Ptosis regressed and limited |
| 77/M        | Diplopia on left gaze | Left mild limitation of extraocular muscle movement in all directions, sensory disturbance in the left V1 and V2 | DLBL | Gamma Knife | *Local tumor control |
| 59/F        | Diplopia and right facial hypesthesia | Right VI palsy and sensory disturbance affecting all three divisions of the right V | DSBL | RT | Partial improvement |
| 78/M        | Painful ophthalmoplegia | Left III palsy, bilateral VI palsy and sensory disturbance affecting left V1,2,3 | ML | - | Rapidly fatal |
| 71/M        | Diplopia | Left partial III palsy without involvement of the pupil | DLBL | NA | NA |
| 89/F        | Diplopia and left ptosis | Left complete III palsy without involvement of the pupil | DLBL | CT | Partial improvement |
| Present case | Diplopia with ocular pain | Incomplete left III and right VI palsy, and sensory loss of the left V1 | DLBL | CT | Partial improvement |

Table 1: CS involvement in NHL
The patient was referred to medical oncology department for a staging work-up, including bone marrow biopsy, which was negative. It was classified as stage IV according the Ann Arbor classification [3].

The patient received chemotherapy consisting of four cycles of R-CHOP (Rituximab, cyclophosphamide, Hydroxydaunomycin, oncovin, and prednisone) and intrathecal administration of methotrexate and hydrocortisone. Following four cycles of intravenous and intrathecal chemotherapy, the right oculomotor nerve palsy was completely resolved. There was partial improvement of enhancing lesion noted on follow-up MRI (six months from onset) (Figure 11). The patient is currently under regular follow-up monthly in the medical oncology department.

Discussion

The manifestations of NHL are numerous, the most common being painless and progressive enlargement of the cervical or other groups of lymph nodes [4]. Approximately 10% to 34% of all NHL arise from extranodal sites [5].

Of these, nasal or paranasal lymphomas account 0.17% of all malignant extranodal lymphomas. They occur either as a metastasis from systemic lymphoma or invasion from a nasal or pharyngeal primary lymphoma [2].

The onset and course of NHL are variable and rapid dissemination is common in patients with neurologic involvement [4]. In rare cases, involvement of the CS can be the inaugural sign of lymphoma and neurologic signs may appear rapidly as in our patient. Presentation of lymphoma with CS involvement are no specific and may present with painful ophthalmoplegia, chemoisa, proptosis, Horner’s syndrome and sensory deficits in the first or second division of the trigeminal nerve [6].

Few case series of CS involvement in NHL are reported in the literature. The clinical characteristics of these cases are summarized in Table 1.

The spread of tumor to leptomeninges is the most common pathogenesis of CS involvement by NHL. Leptomeningeal spread manifests by the presence of lymphoma cells involving the meningeal membranes and CSF. Hematogenous spread is less common, but lymphoma can form nodular deposits by infiltration from the subarachnoid space through the Virchow-Robin spaces [7].

Radiologic examination is very important in the diagnosis of patients with CS lymphoma. On MRI the lymphoma enlarges the CS without compressing the intracavernous ICA. It is usually isohypointense on both T1 and T2-weighted images and enhances homogeneously [8]. Bilateral CS involvements by NHL constitute a diagnostic challenge, particularly when appearing at the presentation of the disease. In fact, a wide range of disorders can affect the CS involving the CS and increases enhancement along the lateral border of the CS [8].

Inflammatory lesions such as Wegener granulomatosis, sarcoidosis and Tolosa Hunt syndrome have to be considered [9]. On MRI, the CS is usually iso or hypointense on T1-weighted imaging and enhances homogeneously. Hypointensity on T2-weighted imaging may be seen with chronic inflammation representing fibrous tissue [6].

Further complementary examinations play a crucial role in diagnosis and management of conditions affecting the CS. In NHL’s CS involvement, biopsy of associated locations usually confirms the diagnosis as in the literature and herein reported case. When CS involvement is solitary, surgical biopsy of this location is mandatory [10,11].

NHL treatment include aggressive chemotherapy and radiotherapy as the clinical characteristics are rapid growth and poor prognosis [12].

Literature suggests that the best treatment outcomes are obtained with the R-CHOP regimen, given at three-week intervals [13]. Intrathecal methotrexate and hydrocortisone reduces CNS recurrence and improves survival in aggressive NHL [14]. In our case, the right oculomotor nerve palsy and enhancing lesion noted on follow-up MRI were improved over the course of chemotherapy [15-24].

Conclusion

NHL should be considered in the differential diagnosis of CSS and a work-up of other focal involvement is mandatory. The diagnosis rests largely on imaging and biopsy results. Aggressive combined modality treatment appears to improve survival.

References

1. Taylor JW, Flanagan EP, O’Neill BP, Siegal T, Omuro A, et al. (2013) Primary leptomeningeal lymphoma International Primary CNS Lymphoma Collaborative Group report. Neurology 81: 1690-1696.

2. Abbondanzo SL, Wenig BM (1995) Non-Hodgkin’s lymphoma of the sinonasal tract. A clinicopathologic and immunophenotypic study of 120 cases. Cancer 75: 1281-1291.

3. Rosenberg SA (1977) Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas. Cancer Treat Rep 61: 1023.

4. Zelenetz AD, Abramson JS, Advani RH, Andreamis CB, Byrd JC, et al. (2010) Non-Hodgkin’s lymphomas. J Natl Compr Canc Netw 8: 288-334.

5. Freeman C, Berg JW, Cutter SJ (1972) Occurrence and prognosis of extranodal lymphomas. Cancer 29: 252-260.

6. Tang Y, Booth T, Seward M, Solbach T, Wilhelm T (2010) The imaging of conditions affecting the cavernous sinus. ClinRadial 65: 937-945.

7. Giglio P, Gilbert MR (2006) Neurologic complications of non-Hodgkin’s lymphoma. Curr Hematol Malig Rep 1: 214-219.

8. Lee JH, Lee HK, Park JK, Choi CG, Suh DC (2003) Cavernous sinus syndrome: Clinical features and differential diagnosis with MR imaging. Am J Roentgenol 181: 583-590.

9. Attou H, Rahmeh F, Ziegler F (2000) Lymphome du sinus caverneux mimant un syndrome de Tolosa-Hunt. Rev Medecine Interne 21: 795-798.

10. Slamovits TL, Cahlil KV, Sobrony PA, Dekker A, Johnson BL (1983) Orbital fine-needle aspiration biopsy in patients with cavernous sinus syndrome. J Neurosurg 59: 1037-1042.

11. Sindou M, Chavez JM, Saint Pierre G, Jouvet A (1997) Percutaneous biopsy of cavernous sinus tumors through the foramen ovale. Neurosurgery 40: 106-111.

12. Arimoto H, Shirotani T, Nakao H, Hashizume K, Sakai Y, et al. (2000) Primary Malignant Lymphoma of the Cavernous Sinus. Neurol Med Chir 40: 275-279.

13. Ansell SM (2015) Non-Hodgkin lymphoma: Diagnosis and treatment. In: Mayo Clinic Proceedings 1152-1163.

14. Tomita N, Kodama F, Kanomori H, Motomura S, Ishigatsubo Y (2002) Prophyllactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma. Cancer 95: 576-580.

15. Crocker LG, Lang GE (1966) Cavernous sinus thrombosis mimicked by CNS lymphoma. JAMA 195: 969-969.

16. Fowler TJ, Earl CJ, McAllister VL, McDonald WI (1975) Tolosa-Hunt syndrome. The dangers of an eponym. Br J Ophthalmol 59: 149-154.
17. Mitsumoto H, Sweeney PJ (1979) Oculomotor palsy from malignant lymphoma. Cleve Clin Q 47: 333-338.
18. Kori SH, Mitsumoto H (1982) Cavernous sinus involvement in lymphoma patients. Neurology 32: A74.
19. Julien J, Ferrer X, Drouillard J, Philippe JC, Desbordes P (1984) Cavernous sinus syndrome due to lymphoma. J NeurolNeurosurg Psychiatry 47: 558-560.
20. Post MJD, Mendez DR, Kline LB, Acker JD, Glaser JS (1985) Metastatic disease to the cavernous sinus: Clinical syndrome and CT diagnosis. J Comput Assist Tomogr 9: 115-120.
21. Delpassand ES, Kirkpatrick JB (1988) Cavernous sinus syndrome as the presentation of malignant lymphoma: case report and review of the literature. Neurosurgery 23: 501-504.
22. Ceyhan M, Erdem G, Kanra G, Kaya S, Önerci M (1994) Lymphoma with bilateral cavernous sinus involvement in early childhood. Pediatr Neurol 10: 67-69.
23. Nakatomi H, Sasaki T, Kawamoto S, Fujimaki T, Furuya K, et al. (1996) Primary cavernous sinus malignant lymphoma treated by gamma knife radiosurgery: case report and review of the literature. Surg Neurol 46: 272-278.
24. Sato H, Hashimoto T, Yoneda S, Hirabayashi K, Oguchi K, et al. (2011) Lymphoma as a cause of isolated oculomotor nerve palsy. J Clin Neurosci 18: 1256-1258.